Literature DB >> 28839956

CRISPR-barcoding in non small cell lung cancer: from intratumor genetic heterogeneity modeling to cancer therapy application.

Federica Zito Marino1,2, Marina Accardo1, Renato Franco1.   

Abstract

Entities:  

Year:  2017        PMID： 28839956      PMCID： PMC5542960          DOI： 10.21037/jtd.2017.06.27

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  14 in total

1.  Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.

Authors:  Yao-Wen Kuo; Shang-Gin Wu; Chao-Chi Ho; Jin-Yuan Shih
Journal:  J Thorac Oncol       Date:  2010-12       Impact factor: 15.609

2.  Studying clonal dynamics in response to cancer therapy using high-complexity barcoding.

Authors:  Hyo-eun C Bhang; David A Ruddy; Viveksagar Krishnamurthy Radhakrishna; Justina X Caushi; Rui Zhao; Matthew M Hims; Angad P Singh; Iris Kao; Daniel Rakiec; Pamela Shaw; Marissa Balak; Alina Raza; Elizabeth Ackley; Nicholas Keen; Michael R Schlabach; Michael Palmer; Rebecca J Leary; Derek Y Chiang; William R Sellers; Franziska Michor; Vesselina G Cooke; Joshua M Korn; Frank Stegmeier
Journal:  Nat Med       Date:  2015-04-13       Impact factor: 53.440

3.  ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

Authors:  Sanjay Popat; David Gonzalez; Toon Min; John Swansbury; Melissa Dainton; James G Croud; Alexandra J Rice; Andrew G Nicholson
Journal:  Lung Cancer       Date:  2011-08-19       Impact factor: 5.705

4.  EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations.

Authors:  M Tiseo; F Gelsomino; D Boggiani; B Bortesi; M Bartolotti; C Bozzetti; G Sammarelli; E Thai; A Ardizzoni
Journal:  Lung Cancer       Date:  2010-12-18       Impact factor: 5.705

5.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

Authors:  Alexa B Turke; Kreshnik Zejnullahu; Yi-Long Wu; Youngchul Song; Dora Dias-Santagata; Eugene Lifshits; Luca Toschi; Andrew Rogers; Tony Mok; Lecia Sequist; Neal I Lindeman; Carly Murphy; Sara Akhavanfard; Beow Y Yeap; Yun Xiao; Marzia Capelletti; A John Iafrate; Charles Lee; James G Christensen; Jeffrey A Engelman; Pasi A Jänne
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

Review 6.  Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical application.

Authors:  Paolo Maione; Paola Claudia Sacco; Assunta Sgambato; Francesca Casaluce; Antonio Rossi; Cesare Gridelli
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

Review 7.  Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy.

Authors:  Bin-Chi Liao; Chia-Chi Lin; Jin-Yuan Shih; James Chih-Hsin Yang
Journal:  Ther Adv Med Oncol       Date:  2015-09       Impact factor: 8.168

8.  Crizotinib Response in a Late Relapse of ALK-positive Lung Adenocarcinoma.

Authors:  Federica Zito Marino; Alessandro Morabito; Cesare Gridelli; Gaetano Rocco; Giuseppina Liguori; Nicla De Rosa; Gerardo Botti; Renato Franco
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-10

Review 9.  Translational implications of tumor heterogeneity.

Authors:  Mariam Jamal-Hanjani; Sergio A Quezada; James Larkin; Charles Swanton
Journal:  Clin Cancer Res       Date:  2015-03-15       Impact factor: 12.531

10.  Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.

Authors:  Emilio Bria; Sara Pilotto; Eliana Amato; Matteo Fassan; Silvia Novello; Umberto Peretti; Tiziana Vavalà; Stefania Kinspergher; Luisella Righi; Antonio Santo; Matteo Brunelli; Vincenzo Corbo; Eliana Giglioli; Isabella Sperduti; Michele Milella; Marco Chilosi; Aldo Scarpa; Giampaolo Tortora
Journal:  Oncotarget       Date:  2015-05-20
View more
  1 in total

Review 1.  Overview on Clinical Relevance of Intra-Tumor Heterogeneity.

Authors:  Giorgio Stanta; Serena Bonin
Journal:  Front Med (Lausanne)       Date:  2018-04-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.